KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: results of a post-hoc analysis from the AReSVi-006 trial.

Jonathan De Smedt, Olivier Gruselle, Lionel Sacconnay, Delphine Baup, Christophe Lambert, Stebin Xavier, Francesca Crudele, Aurélie Olivier, Yannick Vanloubbeeck, Marie Van der Wielen, Marie-Pierre David, Nancy Dezutter, Lucile Warter

EBioMedicine 128 106296

PMID42172919
PMCIDPMC13224123
DOI10.1016/j.ebiom.2026.106296
发表日期2026-05-22
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 flow diagram;Fig. 4:非 KM 图。
摘要

摘要

BACKGROUND: All currently approved RSV vaccines/monoclonal antibodies target the prefusion conformation of the F protein (preF). Amino acid (aa) variations in RSV F are increasingly observed, though their impact on vaccine efficacy (VE) remains unknown. We characterised F sequences of isolates from the phase 3 efficacy trial (AReSVi-006; NCT04886596) of the AS01E-adjuvanted RSV preF-based vaccine (adjuvanted RSVPreF3), evaluated their worldwide representativity, and assessed VE against predominant sequences. METHODS: RSV F aa sequences associated with PCR-confirmed RSV-lower respiratory tract disease (LRTD)/acute respiratory illnesses (ARIs) in AReSVi-006 (in adults aged ≥ 60 years, over three RSV seasons) were characterised and compared to the RSVPreF3 sequence and F sequences reported in public databases during the same period. VE against predominant RSV F sequences was estimated (post-hoc analyses). FINDINGS: We identified 19 RSV-A and 27 RSV-B F sequences, differing with 6-25 aa from RSVPreF3; these were representative of worldwide circulating strains during the trial. Two RSV-A and three RSV-B sequences were associated with most RSV-LRTD/ARI cases. The distribution of cases between vaccinated and placebo groups and VE estimates were within similar ranges in each RSV season across the predominant sequences. The aa sequences with the smallest and largest numbers of mutations compared to RSVPreF3 were not consistently associated with the highest and lowest VE estimates against RSV-LRTD/ARI. INTERPRETATION: Our findings support the efficacy of adjuvanted RSVPreF3 across a broad set of RSV strains, representative of globally circulating strains. VE was maintained irrespective of distance to RSVPreF3 in terms of the number of aa variations. FUNDING: GSK.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Schematic representation of the naming convention used in the study for RSV sequences. An example is provided to illustrate how the naming of each sequence in the study was developed. aa, amino acid; RSV, respiratory syncytial virus.
非 KM Figure
Fig. 2Geographical distribution and frequency of the different combinations of amino acid variations at antigenic sites Ø, I, II, III, IV, and V among RSV F sequences reported in public databases during 2021–2024 and from RSV-ARI samples in the AReSVi-006 clinical trial, overall (A) and by geographical region (B). Only combinations with frequency ≥5% in the analysis of sequences reported in public databases and/or across at least one of the three AReSVi-006 RSV seasons are shown. In the column with sequence names, predominant combinations (overall frequency ≥10% in at least one of the periods considered) are highlighted in grey, with darker shades corresponding to higher overall frequency. The frequency of each combination in each RSV season is shown as horizontal bars (purple for the global analysis and blue for the AReSVi-006 trial), and values are indicated. The table in panel A indicates RSV-A and RSV-B combinations, with cells highlighted in orange representing mutated amino acid positions relative to the RSVPreF3 sequence; numbers in the column headers indicate amino acid positions within the RSV F0 protein. ARI, acute respiratory illness; GA, global analysis; N, number of sequences; RSV, respiratory syncytial virus; S, season. Note: RSV F sequences from the 2021–2022 period were identified retrospectively. To ensure consistency across analyses, these variants were assigned combination names based on the latest definitions established during the initial analysis. Mutations with <1% incidence in other periods were not considered, to maintain comparability.
非 KM Figure
Fig. 3Overview of tested and sequenced RSV-positive samples from the AReSVi-006 clinical trial. ARI, acute respiratory illness; LRTD, lower respiratory tract disease; N, number of samples; PCR, polymerase chain reaction; RSV, respiratory syncytial virus. Note: a These three samples were not tested; b Not all fully sequenced samples were included in the vaccine or placebo group counts (only sequences with unambiguous amino acids in the antigenic sites were classified accordingly).
非 KM Figure
Fig. 4Vaccine efficacy against first occurrence of confirmed RSV-LRTD across predominant RSV F sequences in the adjuvanted RSVPreF3 single-dose group (RSV single-dose group) of the AReSVi-006 trial. Cases were reported from day 15 post-dose 1 up to efficacy data lock point (30 September 2022) or up to dose 2 administration for S1, from day 15 post-dose 2 up to efficacy data lock point (30 September 2023) or up to dose 3 administration for S2, and from start of S3 (1 October 2023) to efficacy data lock point (30 April 2024) for S3. For each sequence, positions in the preF 3D structures that are exhibiting amino acid variation compared to RSVPreF3 are represented in orange. aa, amino acid; CI, confidence interval; LRTD, lower respiratory tract disease; n, number of participants with at least one confirmed RSV-LRTD case; N, number of participants included in the analyses (modified exposed set for S1 and dose 2-modified exposed population for S2 and S3, which included all the participants who had received vaccine or placebo and did not report an RSV-related acute respiratory illness before day 15 post-dose 1 or post-dose 2, respectively); preF, prefusion; RSV, respiratory syncytial virus; S, season. Notes: The case definition for RSV-LRTD was: ≥2 lower respiratory symptoms/signs for ≥24 hours including ≥1 lower respiratory sign OR ≥3 lower respiratory symptoms for ≥24 hours, with ≥1 RSV-positive swab detected by quantitative reverse transcriptase-polymerase chain reaction. In S1, all participants vaccinated with adjuvanted RSVPreF3 had received a single dose of the vaccine, so they were all included in the RSV single-dose group. Error bars indicate 95% CIs; arrows denote cases where the lower limit of the 95% CI extends below −100%.
非 KM Figure